⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1521464 | 0.84 | — | — | |
| SCHEMBL432942 | 0.77 | — | — | |
| SCHEMBL28343468 | 0.76 | — | — | |
| SCHEMBL2990283 | 0.69 | — | — | |
| SCHEMBL8585245 | 0.66 | — | — | |
| SCHEMBL28212911 | 0.65 | — | — | |
| SCHEMBL3336218 | 0.64 | CA4 (0.37) | — | |
| SCHEMBL19953102 | 0.64 | — | — | |
| SCHEMBL28343467 | 0.62 | — | — | |
| SCHEMBL17202511 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 379 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118324846-A | Bufogargarizin A preparation method | 南方科技大学 | 2024-07-12 | — | — | CN | claimed |
| CN-117486934-A | Preparation method of chemiluminescent agent and chemiluminescent agent | 苏州亚科科技股份有限公司 | 2024-02-02 | — | — | CN | claimed |
| CN-116574033-A | Phenylalanine derivative containing alkynyl and benzophenone groups and synthesis method | 中国人民解放军军事科学院防化研究院 | 2023-08-11 | — | — | CN | claimed |
| CN-116082351-A | Synthesis method and application of photoaffinity probe reagent 3- (3-ethanol-3H-biaziridine) propiolactone | 宁波礼达先导生物技术有限公司 | 2023-05-09 | — | — | CN | claimed |
| CN-113461771-B | Preparation method of sodium-potassium ATPase inhibitor | 南方科技大学 | 2022-09-30 | — | — | CN | claimed |
| CN-114466881-A | Fluorinated polyether-based compound | 大金工业株式会社 | 2022-05-10 | — | — | CN | claimed |
| CN-113461771-A | Preparation method of sodium-potassium ATPase inhibitor | 南方科技大学 | 2021-10-01 | — | — | CN | claimed |
| EP-1353929-B1 | STREPTOGRAMIN DERIVATIVES PREPARATION THEREOF AND COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2005-03-16 | — | — | EP | claimed |
| EP-1353929-A2 | STREPTOGRAMIN DERIVATIVES PREPARATION THEREOF AND COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 2003-10-22 | — | — | EP | claimed |
| WO-2002050084-A2 | STREPTOGRAMIN DERIVATIVES PREPARATION THEREOF AND COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 2002-06-27 | — | — | WO | claimed |
| CN-119997953-A | Alpha protein kinase 1 inhibitors for the treatment of kidney diseases and kidney related diseases | 上海药苑生物科技有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-119855815-A | KRAS mutant protein inhibitor, and preparation method and application thereof | 甘李药业股份有限公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-116082351-B | Synthesis method and application of photoaffinity probe reagent 3- (3-ethanol-3H-biaziridine) propiolactone | 宁波礼达先导生物技术有限公司 | 2024-09-17 | — | — | CN | disclosed |
| CN-118591540-A | KRAS degrading compounds comprising cyclic 2-amino-3-cyanothiophenes | 勃林格殷格翰国际有限公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-118525018-A | Bialkyne compound and application thereof | 上海艾力斯医药科技股份有限公司 | 2024-08-20 | — | — | CN | disclosed |
| CN-1759111-A | Imidazol-4-yl-ethynyl-pyridine derivatives | HOFFMANN LA ROCHE (CH) | 2006-04-12 | — | — | CN | disclosed |
| EP-1353929-B1 | STREPTOGRAMIN DERIVATIVES PREPARATION THEREOF AND COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2005-03-16 | — | — | EP | disclosed |
| EP-1353929-A2 | STREPTOGRAMIN DERIVATIVES PREPARATION THEREOF AND COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002050084-A2 | STREPTOGRAMIN DERIVATIVES PREPARATION THEREOF AND COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 2002-06-27 | — | — | WO | disclosed |
| CN-1330647-A | 4-alkenyl (and alkynyl) oxindoles as inhibitors of cell cycle protein dependent kinases, in particular CDK2 | HOFFMANN LA ROCHE (CH) | 2002-01-09 | — | — | CN | disclosed |